NIH funding opportunities

Faculty of Medicine and Health Sciences: Research Development and Support 12 Dec 2016 (#43)

[Click on blue hyperlink for further information]

*The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.*

*Please be advised that you **must contact the Research Grants Management Office (RGMO) Pre-Awards** (Dr Christa de Vries cdevries@sun.ac.za) **as soon as possible to inform of your intent to apply and then confirm at least 30 days before the submission date**. The NIH grant is submitted institutionally. **All final application documents MUST reach the RGMO seven (7) workdays before NIH application due date.***

Important notices

- **NIH To Enhance the Grant Closeout Process Next Month Effective January 1, 2017, NIH will replace the Final Progress Report with a Final Research Performance Progress Report, which grantees will be able to complete and submit through a new eRA Commons module.**
- **Help Shape NIH Strategies for Data Management and Sharing To further develop priorities for data management, sharing, and citation, as well as strategies for expanding the Data Sharing Policy, NIH issued a request for information soliciting public feedback on data sharing stewardship.**
- **To Name or Not To Name In your application, we advise you to name only formal co-investigators, consultants, and collaborators as key personnel. Avoid the temptation to list largely uninvolved people or suggest reviewers.**
- **Notice of Intent to Publish a Funding Opportunity Announcement for Basic Mechanisms of Brain Development for Substance Use and Dependence (R01) (NOT-DA-17-004)**
- **Notice of Intent to Publish a Funding Opportunity Announcement for Discovering Novel Targets: The Molecular Genetics of Drug Addiction and Related Co-Morbidities (R01) (NOT-DA-17-005)**
- **Request for Information (RFI): Biological Mechanisms/Pathways of the Combined Effects of Chemical and Non-chemical Stressors Associated with Atherosclerosis (NOT-ES-17-003)**
- **Collaborative Research in Computational Neuroscience (CRCNS) Innovative Approaches to Science and Engineering Research on Brain Function (NOT-MH-17-003)**

1. Revision Applications for U.S-South Africa Program for Collaborative Biomedical Research

Letter of Intent due date: 30 days prior to the application due date **Hyperlink:** (RFA-AI-16-082) **Type: R01**

Application Due Date: March 28, 2017. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (to both Grants.gov and eRA Commons) on the application due date.

The purpose of this Funding Opportunity Announcement (FOA) is to provide funding to expand specific activities under the U.S.-South Africa Program for Collaborative Biomedical Research (R01). The purpose of the opportunities under the revision application is to enhance the pool of investigators in South Africa who are from underrepresented backgrounds in the country's workforce and who are engaged in collaborative research activities in the areas of tuberculosis (TB), HIV/AIDS biomedical and behavioral science, and HIV-related co-morbidities, including malignancies.

Budget: Application budgets are limited to $250,000 per year in total costs for up to two years. Applicants must have at least one year of funding remaining on their grant at the time of submission. A minimum of 67% of the total cost budget should be apportioned to activities that will be conducted in South Africa. Indirect cost for foreign grantees are limited to 8%. F&A costs requested by consortium participants are not included in the direct cost limitation. Awards will be made as revisions to the parent R01 and cannot exceed the project period of the parent award.

2. Revision Applications for U.S.-South Africa Program for Collaborative Biomedical Research

Letter of Intent due date: 30 days prior to the application due date **Hyperlink:** (RFA-AI-16-083) **Type: U01**

Application Due Date: March 28, 2017. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (to both Grants.gov and eRA Commons) on the application due date.

The purpose of this Funding Opportunity Announcement (FOA) is to provide funding to expand specific activities under the U.S.-South Africa Program for Collaborative Biomedical Research (U01). The purpose of the opportunities under the revision application is to enhance the pool of investigators in South Africa who are from underrepresented backgrounds in the country's workforce and who are engaged in collaborative research activities in the areas of tuberculosis (TB), HIV/AIDS biomedical and behavioral science, and HIV-related co-morbidities, including malignancies.

Budget: Application budgets are limited to $250,000 per year in total costs for up to two years, inclusive of the limit of $50,000 per year to support the NIH Intramural investigator's costs attributed to the proposed revision activities. A minimum of 67% of the total cost budget should be apportioned to activities that will be conducted at South African institutions. Applicants may request support for up to 2 years. At the time of award of the revision, there must be two years remaining on the parent award for a two year revision request or one year remaining on the parent award for a one year revision request. Awards will be made as revisions to the parent U01 and cannot exceed the project period of the parent award.

3. Pilot Clinical Trials Targeting HIV-1 Reservoirs in Children

Letter of Intent due date: 30 days prior to the application due date **Hyperlink:** (RFA-AI-16-086) **Type: U01**

Application Due Date: March 14 2017. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (to both Grants.gov and eRA Commons) on the application due date.

The purpose of this Funding Opportunity Announcement (FOA) is to support pilot clinical trials that test interventions to limit or reduce HIV-1 reservoirs in children (birth to 18 years of age at the time of enrollment) on effective suppressive antiretroviral therapy.

Budget: NIAID intends to commit $ 3,150,000 in FY2018 to fund 1-2 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The total project period may not exceed 5 years.

4. Optimizing the HIV Care Continuum for Substance Abusing Populations at High-Risk and/or Living with HIV

Letter of Intent due date: 30 days prior to the application due date **Hyperlink:** (RFA-DA-17-024) **Type: R01**

Application Due Date: May 9, 2017. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (to both Grants.gov and eRA Commons) on the application due date.

This Funding Opportunity Announcement (FOA) encourages research that examines the optimization of multiple components of the care continuum, such as HIV testing (identification) status, linkage and retention in care, and viral suppression for individuals with HIV for substance abusing populations at high-risk and/or living with HIV. There is limited evidence for how strategies that are successful in targeting one part of the HIV care cascade (linkage to care) can be integrated with interventions for other behaviors (ART adherence, retention in care). Moreover, the need to understand how government policies related to financing and clinical recommendations affect care, along with professional norms and the policies and guidelines established within individual clinics or organized systems of care effect the care continuum and HIV clinical outcomes, are critical. This FOA requires that applications include an examination beyond patient-level outcomes alone to include provider practices, system or organizational capacities, policies, and protocols; and structural issues including national, state/provincial or local policies that affect access to substance use and/or HIV care.

Budget: NIH intends to fund an estimate of 3-5 awards, corresponding to a total of $4 million, for fiscal year 2017. Future year amounts will depend on annual appropriations. Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period may not exceed 2 years.

5. Potential Effects of Metformin on Aging and Age-Related Conditions: Small-Scale Clinical Studies and Secondary Analysis of Controlled Clinical Studies

Letter of Intent due date: 30 days prior to the application due date **Hyperlink:** (PA-17-073) **Type: R01**

Application Due Date: Standard dates and Standard AIDS dates . Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (to both Grants.gov and eRA Commons) on the application due date.

Data from clinical studies of metformin in a variety of patient populations suggest that it may have other effects, besides being an antihyperglycemic agent, which warrant further attention in translational aging research. The objective of this FOA is to support research projects (R01), including small-scale physiologic studies in humans or secondary analyses of data and/or stored biospecimens from controlled clinical intervention studies, to increase our understanding of the clinical translational potential of metformin to delay deleterious aging changes or to extend healthy human life span. This includes identification of specific populations particularly likely to benefit from treatment, and/or obtaining information on metformin's human physiologic and cellular effects that would be useful in identifying novel molecular targets.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum period is 5 years.

Brief definitions of some NIH grant mechanisms: *comprehensive list of extramural grant and cooperative agreement activity codes*

D71 - International Research Training Planning Grant: To plan for the preparation of an application for a D43 international research training grant or for a U2R international research training cooperative agreement.

D43 - International Research Training Grants: To support research training programs for US and foreign professionals and students to strengthen global health research and international research collaboration.

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <$500,000 p.a. (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <$275,000 (direct costs).

R03 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for "new investigators"; not renewable; up to 2 years; budget generally <$50,000 (direct costs).

R21/R33 - Phased Innovation: The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

R25 – NIH Education Projects: used in a wide variety of ways to promote an appreciation for and interest in biomedical research, provide additional training in specific areas, and/or to develop ways to disseminate scientific discovery into public health and community applications.

R34 - Clinical Trial Planning Grant Program: To provide support for the initial development of a clinical trial, including the establishment of the research team; the development of tools for data management and oversight of the research; the development of a trial design and other essential elements of the study, such as the protocol, recruitment strategies, and procedure manuals; and to collect feasibility data.

R35 - Outstanding Investigator Award: To provide long term support to an experienced investigator with an outstanding record of research productivity. This support is intended to encourage investigators to embark on long-term projects of unusual potential.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

U24 – Resource-Related Research Projects – Cooperative Agreements: To support research projects contributing to improvement of the capability of resources to serve biomedical research.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

U19 - **Research Program-Cooperative Agreements:** supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. A cooperative agreement research program generally involves the organized efforts of large groups, members of which are conducting research projects designed to elucidate the various aspects of a specific objective.

Glossary of selected acronyms:

FOA Funding Opportunity Announcement

PA Program Announcements *(click on "PA" to search for further funding opportunities)*

RFA Request for Applications *(click on "RFA" to search for further funding opportunities)*

Complete Glossary and acronym list of NIH Terms

NIH National Institutes of Health
Turning Discovery Into Health

Research Development and Support Division (RDSD), Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus. • Enquiries: ***Dr Christa Coetsee*** • Tel: 9838 • Email: cdevries@sun.ac.za